Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for ibandronic acid

  1. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.

    Technology appraisal guidance
    Last updated
    8 July 2019
    View recommendations

    Sections for TA464

  2. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date:  10 June 2027

    Technology appraisal guidance
    Awaiting development

  3. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

    Technology appraisal guidance
    Published
    24 October 2012
    View recommendations

    Sections for TA265

  4. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

    Technology appraisal guidance
    Published
    25 May 2022
    View recommendations

    Sections for TA791